A randomized phase I study of the safety and pharmacokinetics of BI 1291583 in healthy Japanese male subjects

IF 3.1 3区医学 Q2 PHARMACOLOGY & PHARMACY

British journal of clinical pharmacology Pub Date : 2024-09-19 DOI:10.1111/bcp.16249

Yusuke Tadayasu, Donald Sarubbi, Takumi Furuichi, Anastasia Eleftheraki, Shuhei Nakamura, Wiebke Sauter, Ryuzo Hanada

引用次数: 0

Abstract

Bronchiectasis patients face an unmet need for treatment options that reduce inflammation. Cathepsin C inhibition is expected to achieve this by reducing the activation of neutrophil-derived serine proteases. Here, we present safety and pharmacokinetic (PK) data from a Phase I trial evaluating the novel cathepsin C inhibitor BI 1291583 in healthy Japanese male subjects.

查看原文本刊更多论文

关于 BI 1291583 在健康日本男性受试者中的安全性和药代动力学的 I 期随机研究

支气管扩张症患者对减少炎症的治疗方案的需求尚未得到满足。Cathepsin C抑制剂有望通过减少中性粒细胞衍生的丝氨酸蛋白酶的活化来实现这一目标。在此，我们展示了一项 I 期试验的安全性和药代动力学（PK）数据，该试验评估了新型 cathepsin C 抑制剂 BI 1291583 在健康日本男性受试者中的应用情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

British journal of clinical pharmacology 医学-药学

CiteScore

6.30

自引率

8.80%

发文量

419

审稿时长

1 months

期刊介绍： Published on behalf of the British Pharmacological Society, the British Journal of Clinical Pharmacology features papers and reports on all aspects of drug action in humans: review articles, mini review articles, original papers, commentaries, editorials and letters. The Journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry. It also publishes research on new methods, new drugs and new approaches to treatment. The Journal is recognised as one of the leading publications in its field. It is online only, publishes open access research through its OnlineOpen programme and is published monthly.